Covid-19 update: 6375 new cases detected in South Africa in 24 hours



In South Africa, 6,375 new cases of Covid-19 have been identified in the past 24 hours, bringing the total number of laboratory-confirmed cases to 3,921,633.

This increase represents a 19.5% positive rate, according to the National Institute of Infectious Diseases (NICD), a division of the National Health Laboratory Service, announced.

Today, the majority of new cases are in Gauteng (34%), followed by the Western Cape (23%). KwaZulu-Natal accounted for 14%; The Eastern Cape accounted for 10% and the Free State for 7%. The Northern Cape and the Northwest accounted for 4% each; Mpumalanga accounted for 3% and Limpopo 1% of today’s cases.

The country also reported 18 deaths, of which 6 occurred in the last 24-48 hours. This brings the total death toll to date to 100,916.

“Due to ongoing audits by the National Department of Health (NDoH), there may be a buildup of reported deaths from Covid-19,” the NICD said in a statement.

25,025,578 tests were carried out in both the public and private sectors.

Over the past 24 hours, the number of hospitalizations has increased by 134.

WHO approves Chinese vaccine CanSinoBIO against Covid-19

The World Health Organization on Thursday green-lit Chinese manufacturer CanSinoBIO’s Covid-19 vaccine, the ninth shot to receive WHO approval.

The WHO has granted emergency use list (EUL) approval for a single shot Convidecia vaccine as China grapples with a resurgence of the virus caused by the Omicron variant.

It is the third Chinese-made vaccine approved by the UN health agency, after Sinovac and Sinopharm.

According to the WHO, Convidecia was 64% effective against symptomatic disease and 92% effective against severe Covid-19.

“The vaccine meets WHO standards for protection against Covid-19 and… the benefits of the vaccine far outweigh the risks,” the UN health agency said in a statement.

WHO vaccine experts recommended it for people aged 18 and over.

The WHO has stated that Convidecia can be used as a booster dose after completion of the primary series with any other EUL Covid-19 vaccine.

ALSO READ: The Special Tribunal declared illegal the extension of the contract for 4.8 million rand on Covid-19

– Traditional vector method –

The strike has already been deployed in several countries, including China, Argentina, Chile, Malaysia, Mexico and Pakistan.

More than 58 million people have already been vaccinated with the vaccine by the end of 2021, including almost 14 million people in China, according to the WHO.

Currently, WHO has given EUL status to nine Covid-19 vaccines and their variations – Pfizer/BioNTech, AstraZeneca, Janssen, Moderna, Sinovac, Sinopharm, Bharat Biotech, Novavax and CanSinoBIO.

Convidecia is based on a modified human adenovirus. AstraZeneca and Janssen vaccines are also based on viral vector technology.

A more traditional approach uses a genetically engineered version of the common cold adenovirus as a “vector” to pass on the genetic instructions to human cells.

According to the WHO, Convidecia “shows a favorable safety profile in people of different age groups”, inducing a strong immune response with both binding and neutralizing antibodies.

– Seal of Approval –

The EUL process examines the quality, safety and efficacy of vaccines and includes site inspections.

The WHO says EUL approval gives countries, funds, purchasing agencies and communities the confidence that a vaccine meets international standards.

Listing by WHO allows countries to quickly approve and import a vaccine for distribution, especially those that do not have their own regulatory body that meets international standards.

It also opens the door for vaccinations to the Covax Global Vaccine Exchange Center, which aims to ensure equal access to doses worldwide, especially in poorer countries.

The WHO began reviewing current data on the CanSinoBIO vaccine in August.

Other vaccines are also on the way to an EUL decision: the WHO is looking into current data on another Sinopharm vaccine, as well as vaccines from France’s Sanofi, China’s Clover and Zhifei Longcom, and Iran’s Shifa Pharmed.

The EUL process for the Russian satellite Sputnik V has stalled.

Hundreds of vaccine candidates are being developed in laboratories around the world.

WHO is aware of 156 drugs in clinical development (human testing) and 198 drugs in the preclinical stage.

Additional AFP reporting